Aprotinin
- Atc Codes:B02AB01
- CAS Codes:9087-70-1#12407-79-3#11061-94-2
- PHARMGKB ID:9087-70-1#12407-79-3#11061-94-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Trasylol; Germany: Trasylol; Greece: Trasylol; Hungary: Gordox, Trasylol; Ireland: Trasylol; Luxembourg: Iniprol, Trasylol; Malta: Trasylol; Poland: Traskolan, Trasylol; Sweden: Trasylol.
North America
Canada: Trasylol; USA: Trasylol.
Latin America
Brazil: Trasylol.
Asia
Japan: Trasylol.
Drug combinations
Aprotinin and Protein C Concentrate (Human)
Aprotinin, Calcium Chloride, Fibrinogen, and Thrombin
Aprotinin, Collagen, Fibrinogen, and Thrombin
Aprotinin, Calcium Chloride, Factor XIII, Fibrinogen, Fibronectin, Plasminogen, Proteins, and Thrombin
Chemistry
Aprotinin: C~284~H~432~N~84~O~79~S~7~. Mw: 6511.44. (1) Trypsin inhibitor, pancreatic basic; (2) L-Arginyl-L-prolyl-L-aspartyl-L-phenylalanyl-L-cysteinyl-L-leucyl-L-glutamyl-L-prolyl-L-prolyl-L-tyrosyl-L-threonylglycyl-L-prolyl-L-cysteinyl-L-lysyl-L-alanyl-L-arginyl-L-isoleucyl-L-isoleucyl-L-arginyl-L-tyrosyl-L-phenylalanyl-L-tyrosyl-L-asparaginyl-L-alanyl-L-lysyl-L-alanylglycyl-L-leucyl-L-cysteinyl-L-glutaminyl-L-threonyl-L-phenylalanyl-L-valyl-L-tyrosylglycylglycyl-L-cysteinyl-L-arginyl-L-alanyl-L-lysyl-L-arginyl-L-asparaginyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-seryl-L-alanyl-L-glutamyl-L-aspartyl-L-cysteinyl-L-methionyl-L-arginyl-L-threonyl-L-cysteinylglycylglycyl-L-alanine cyclic (5→55), (14→38), (30→51) tris(disulfide). CAS-9087-70-1; CAS-12407-79-3 (ox pancreas basic); CAS-11061-94-2 (ox pancreas basic reduced)(1968).
Pharmacologic Category
Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02AB01).
Mechanism of action
Attenuates coagulation, fibrinolytic and inflammatory pathways by interfering with the chemical mediators (thrombin, plasmin, kallikrein) and protects platelet-expressed glycoproteins from mechanical shear forces.
Therapeutic use
Prevention of perioperative blood loss during coronary artery bypass graft surgery.
Pregnancy and lactiation implications
Teratogenic effects were not observed in animal studies. Use with caution during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to aprotinin or any component of the formulation. Known or suspected exposure within the past 12 months.
Warnings and precautions
High rate of mortality and of heart failure in observational studies. Anaphylactic, hypersensitivity reactions are possible (hypotension is the most frequently reported sign). May cause serious kidney damage (renal dysfunction may occur).